Research

Daraxonrasib and chemotherapy shrink tumors in pancreatic cancer trial

In an early-stage trial of 61 patients with metastatic pancreatic cancer, tumors shrank or disappeared in 60.7% who received daraxonrasib with chemotherapy.

Reported by 4 outlets Saturday, November 21, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

An early-stage trial found that daraxonrasib combined with gemcitabine and nab-paclitaxel shrank or eliminated tumors in patients with metastatic pancreatic cancer who had not yet received treatment for that advanced disease. Of 61 patients, 60.7% had tumors shrink or disappear, including 8.2% whose tumors were no longer detectable on scans. Tumor growth stopped in 90.2% of patients, according to the results presented at the EORTC-NCI-AACR Symposium.

The median time before tumors returned or began growing again was 12.8 months. At 12 months, 76.6% of patients were alive. The reports describe the findings as promising but say they need careful interpretation because the early-phase trial had no group receiving chemotherapy alone. A larger, randomized phase 3 trial, RASolute-303, is comparing daraxonrasib alone and with chemotherapy against chemotherapy alone.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.